Another HDAC6-selective inhibitor, nexturastat, in combination with an anti-PD-1 agent in syngeneic melanoma tumor models demonstrated significantly reduced tumor growth and profound changes in the tumor microenvironment, such as reduction of pro-tumorigenic M2 macrophages along with an increase of effector T-cells [37]. Here, HDAC6 is linked to melanoma.